Eli Lilly
Mounjaro (Tirzepatide)
$1,100.004 pens/month (various doses: 2.5–15mg/0.5ml)($275/pen)Injectable
Dual GIP/GLP-1 receptor agonist — the first of its class, approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). SURMOUNT trials showed up to 22% average body weight reduction. PRESCRIPTION REQUIRED.
Community Rating
4.5★/ 5.0
Concentration
2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, or 15mg per 0.5ml pen
Peptides in this product
Other key ingredients
Tirzepatide (dual GIP/GLP-1 receptor agonist)Sodium phosphate dibasic heptahydrateSodium phosphate monobasic monohydrateSodium chlorideBenzyl alcoholWater for injection
Pros
- ✓Dual GIP and GLP-1 agonism produces greater weight loss than semaglutide in head-to-head studies
- ✓SURMOUNT-1 trial showed up to 22.5% average weight reduction at 15mg — highest of any approved agent
- ✓FDA-approved for type 2 diabetes as Mounjaro and chronic weight management as Zepbound
- ✓Once-weekly injection with a dose-escalation protocol that improves tolerability
Cons
- ✗Prescription only — requires clinical assessment, diagnosis, and physician oversight
- ✗Similar GI side effect profile to semaglutide; nausea and GI discomfort are common
- ✗List price approximately $1,100/month without insurance coverage
- ✗Same contraindications as semaglutide: personal or family history of medullary thyroid carcinoma or MEN2
- ✗Long-term data beyond 3–4 years remains limited as a relatively newer agent
Last verified: 2025-03-01
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.